Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 20/20 | 1.00 |
| ▸ | PPARG | P37231 | 11/20 | 1.00 |
| ▸ | PPARD | Q03181 | 7/20 | 1.00 |
| ▸ | PSEN1 | P49768 | 2/20 | 0.72 |
| ▸ | PSEN2 | P49810 | 2/20 | 0.72 |
| ▸ | APH1B | Q8WW43 | 2/20 | 0.72 |
| ▸ | NCSTN | Q92542 | 2/20 | 0.72 |
| ▸ | APH1A | Q96BI3 | 2/20 | 0.72 |
| ▸ | PSENEN | Q9NZ42 | 2/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2742676 | 1.00 | PPARA (1.00) | PPARAPPARGPPARDPSEN1PSEN2 | |
| SCHEMBL29557298 | 1.00 | PPARA (1.00) | PPARAPPARGPPARDPSEN1PSEN2 | |
| SCHEMBL5111743 | 0.94 | PPARA (0.89) | PPARAPPARGPPARDPSEN1PSEN2 | |
| SCHEMBL5188840 | 0.93 | PPARA (0.86) | PPARAPPARGPPARDPSEN1PSEN2 | |
| SCHEMBL6376945 | 0.92 | PPARA (0.86) | PPARAPPARGPPARDPSEN1PSEN2 | |
| SCHEMBL6375543 | 0.92 | PPARA (0.86) | PPARAPPARGPPARDPSEN1PSEN2 | |
| SCHEMBL6373752 | 0.92 | PPARA (1.00) | PPARAPPARGPPARDPSEN1PSEN2 | |
| SCHEMBL6373745 | 0.92 | PPARA (1.00) | PPARAPPARGPPARDPSEN1PSEN2 | |
| SCHEMBL5112917 | 0.92 | PPARA (0.84) | PPARAPPARGPPARDPSEN1PSEN2 | |
| SCHEMBL5125346 | 0.92 | PPARA (0.84) | PPARAPPARGPPARDPSEN1PSEN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1184366-B1 | SUBSTITUTED PHENYLPROPIONIC ACID DERIVATIVES AS AGONISTS TO HUMAN PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR ALPHA(PPAR) | KYORIN SEIYAKU KK (JP) | 2005-02-09 | — | — | EP | claimed |
| US-6506797-B1 | Activate by binding to receptor as ligands of human peroxisome preliferant-activated receptor alpha alpha ), and exhibit potent decreasing action on lipids in blood (cholesterol and triglyceride). | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2003-01-14 | — | — | US | claimed |
| EP-1184366-A1 | SUBSTITUTED PHENYLPROPIONIC ACID DERIVATIVES AS AGONISTS TO HUMAN PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR ALPHA(PPAR) | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2002-03-06 | — | — | EP | claimed |
| US-20110112097-A1 | Substituted imidazoline-2,4-diones, process for preparation thereof, medicaments comprising these compounds and use thereof | SANOFI-AVENTIS (FR) | 2011-05-12 | — | — | US | disclosed |
| US-20110112097-A1 | Substituted imidazoline-2,4-diones, process for preparation thereof, medicaments comprising these compounds and use thereof | SANOFI-AVENTIS (FR) | 2011-05-12 | — | — | US | disclosed |
| US-20100240580-A1 | AZOLOARINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, PHARMACEUTICALS CONTAINING THESE COMPOUNDS AND THE USE THEREOF | SANOFI-AVENTIS (FR) | 2010-09-23 | — | — | US | disclosed |
| US-20100240580-A1 | AZOLOARINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, PHARMACEUTICALS CONTAINING THESE COMPOUNDS AND THE USE THEREOF | SANOFI-AVENTIS (FR) | 2010-09-23 | — | — | US | disclosed |
| EP-1614417-A4 | SOLID PREPARATION FOR ORAL USE | KYORIN SEIYAKU KK (JP) | 2007-08-29 | — | — | EP | disclosed |
| WO-2006093354-A1 | PRODUCTION INTERMEDIATE OF (S)-2-[3-(N-{[4-(4-FLUOROPHENOXY)PHENYL]METHYL}CARBAMOYL)-4-METHOXYPHENYLMETHYL]BUTANOIC ACID | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2006-09-08 | — | — | WO | disclosed |
| WO-2006093354-A1 | PRODUCTION INTERMEDIATE OF (S)-2-[3-(N-{[4-(4-FLUOROPHENOXY)PHENYL]METHYL}CARBAMOYL)-4-METHOXYPHENYLMETHYL]BUTANOIC ACID | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2006-09-08 | — | — | WO | disclosed |
| WO-2006090756-A1 | NOVEL PREVENTIVE OR REMEDY FOR LIPID METABOLISM DISORDER, OBESITY AND DIABETES AND USE THEREFOR | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2006-08-31 | — | — | WO | disclosed |
| WO-2004091600-A1 | SOLID PREPARATION FOR ORAL USE | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2004-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240580-A1 | AZOLOARINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, PHARMACEUTICALS CONTAINING THESE COMPOUNDS AND THE USE THEREOF | CYP3A43, CYP11B1, CYP11B2 | PPARA 1974/4885PPARG 2414/4885PPARD 1607/4885 |
| US-20110112097-A1 | Substituted imidazoline-2,4-diones, process for preparation thereof, medicaments comprising these compounds and use thereof | GIPR, PGC, DDC | PPARA 91/4885PPARG 33/4885PPARD 43/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.